Literature DB >> 24131181

More than just reassurance on tiotropium safety.

Christine R Jenkins1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24131181     DOI： 10.1056/NEJMe1310107

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

Review 1.  Advances in device and formulation technologies for pulmonary drug delivery.

Authors:  John Gar Yan Chan; Jennifer Wong; Qi Tony Zhou; Sharon Shui Yee Leung; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2014-04-12       Impact factor: 3.246

Review 2.  Olodaterol: first global approval.

Authors:  Andrew Gibb; Lily P H Yang
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

3.  Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.

Authors:  David Mg Halpin; Ronald Dahl; Christoph Hallmann; Achim Mueller; Donald Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-05

4.  Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.

Authors:  Anthony D D'Urzo; Edward M Kerwin; Kenneth R Chapman; Marc Decramer; Robert DiGiovanni; Peter D'Andrea; Huilin Hu; Pankaj Goyal; Pablo Altman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-08-11

5.  Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study.

Authors:  Francesco Trotta; Roberto Da Cas; Maja Rajevic; Mariangela Rossi; Giuseppe Traversa
Journal:  BMJ Open       Date:  2015-05-25       Impact factor: 2.692

Review 6.  Tiotropium Bromide in Chronic Obstructive Pulmonary Disease and Bronchial Asthma.

Authors:  Alcibey Alvarado-Gonzalez; Isabel Arce
Journal:  J Clin Med Res       Date:  2015-09-25

7.  Cardiovascular safety of tiotropium Respimat vs HandiHaler in the routine clinical practice: A population-based cohort study.

Authors:  Francesco Trotta; Stefania Spila-Alegiani; Roberto Da Cas; Maja Rajevic; Valentino Conti; Mauro Venegoni; Mariangela Rossi; Giuseppe Traversa
Journal:  PLoS One       Date:  2017-04-21       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.